Humacyte Inc (HUMA) - Net Assets
Based on the latest financial reports, Humacyte Inc (HUMA) has net assets worth $3.11 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($116.37 Million) and total liabilities ($113.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check HUMA tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.11 Million |
| % of Total Assets | 2.67% |
| Annual Growth Rate | -46.47% |
| 5-Year Change | -97.46% |
| 10-Year Change | N/A |
| Growth Volatility | 196.27 |
Humacyte Inc - Net Assets Trend (2019–2025)
This chart illustrates how Humacyte Inc's net assets have evolved over time, based on quarterly financial data. See Humacyte Inc (HUMA) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Humacyte Inc (2019–2025)
The table below shows the annual net assets of Humacyte Inc from 2019 to 2025. For live valuation and market cap data, see HUMA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.11 Million | +105.90% |
| 2024-12-31 | $-52.67 Million | -488.82% |
| 2023-12-31 | $13.55 Million | -88.42% |
| 2022-12-31 | $116.93 Million | -4.29% |
| 2021-12-31 | $122.17 Million | +72.87% |
| 2020-12-31 | $70.67 Million | -46.54% |
| 2019-12-31 | $132.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Humacyte Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40527600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.00K | 0.64% |
| Other Components | $729.94 Million | 23478.19% |
| Total Equity | $3.11 Million | 100.00% |
Humacyte Inc Competitors by Market Cap
The table below lists competitors of Humacyte Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JIUMAOJIU INTL HLDGS LTD
F:3YU
|
$215.12 Million |
|
TBI Motion Technology Co Ltd
TW:4540
|
$215.20 Million |
|
Audix Corp
TW:2459
|
$215.25 Million |
|
Spok Holdings Inc
NASDAQ:SPOK
|
$215.35 Million |
|
CAMP4 THERAPEUTICS CORPORATION
NASDAQ:CAMP
|
$214.97 Million |
|
Oryzon Genomics SA
MC:ORY
|
$214.95 Million |
|
The Gold Bond Group Ltd
TA:GOLD
|
$214.87 Million |
|
Medeon Biodesign
TWO:6499
|
$214.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Humacyte Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -52,669,000 to 3,109,000, a change of 55,778,000.
- Net loss of 40,833,000 reduced equity.
- New share issuances of 103,450,000 increased equity.
- Other factors decreased equity by 6,839,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-40.83 Million | -1313.38% |
| Share Issuances | $103.45 Million | +3327.44% |
| Other Changes | $-6.84 Million | -219.97% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Humacyte Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 49.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.15x to 49.29x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $6.57 | $0.97 | x |
| 2020-12-31 | $5.68 | $0.97 | x |
| 2021-12-31 | $3.06 | $0.97 | x |
| 2022-12-31 | $1.13 | $0.97 | x |
| 2023-12-31 | $0.13 | $0.97 | x |
| 2024-12-31 | $-0.44 | $0.97 | x |
| 2025-12-31 | $0.02 | $0.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Humacyte Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1313.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2003.58%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 37.43x
- Recent ROE (-1313.38%) is below the historical average (-331.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -64.62% | -1380.67% | 0.04x | 1.28x | $-98.64 Million |
| 2020 | -94.13% | -4461.70% | 0.01x | 1.51x | $-73.59 Million |
| 2021 | -21.67% | -2096.36% | 0.00x | 2.35x | $-38.69 Million |
| 2022 | -10.23% | -764.54% | 0.01x | 1.75x | $-23.66 Million |
| 2023 | -817.78% | 0.00% | 0.00x | 9.47x | $-112.13 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-143.43 Million |
| 2025 | -1313.38% | -2003.58% | 0.02x | 37.43x | $-41.14 Million |
Industry Comparison
This section compares Humacyte Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Humacyte Inc (HUMA) | $3.11 Million | -64.62% | 36.43x | $215.11 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more